RECURSION PHARMACEUTICALS, INC. Operating Lease Liability
RECURSION PHARMACEUTICALS, INC. (RXRX) had Operating Lease Liability of $59.31 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-25
- 2025-12-31: Operating Lease, Liability $59.31M.
- 2024-12-31: Operating Lease, Liability $81.05M.
- 2024-09-30: Operating Lease, Liability $61.90M.
- 2024-06-30: Operating Lease, Liability $58.85M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $59.31M 10-K · filed 2026-02-25 |
| 2024-12-31 | $81.05M 10-K · filed 2025-02-28 |
| 2024-09-30 | $61.90M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $58.85M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $49.85M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $49.53M 10-K · filed 2024-02-29 |
| 2023-09-30 | $49.66M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $51.07M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $51.21M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $50.37M 10-K · filed 2023-02-27 |
| 2022-09-30 | $51.53M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $53.01M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $51.40M 10-Q · filed 2022-05-10 |
| 2022-01-01 | $47.80M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |